$INDP
Indaptus Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223016268 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.015M $2.575M $2.105M
YoY Change -14.74% 22.34% 1594.15%
% of Gross Profit
Research & Development $1.480M $1.880M $1.297M
YoY Change -1.7% 44.93% 164.87%
% of Gross Profit
Depreciation & Amortization $320.00 $321.00 $530.00
YoY Change -40.74% -39.43% 152.38%
% of Gross Profit
Operating Expenses $3.495M $4.455M $3.402M
YoY Change -9.67% 30.95% 454.1%
Operating Profit -$3.495M -$4.455M -$3.402M
YoY Change -9.67% 30.95%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $250.2K $201.9K $36.92K
YoY Change 641.15% 446.93% 2281.94%
Pretax Income -$3.245M -$4.253M -$3.365M
YoY Change -15.39% 26.39% 449.48%
Income Tax
% Of Pretax Income
Net Earnings -$3.245M -$4.253M -$3.365M
YoY Change -15.39% 26.39% 449.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.51 -$0.41
Diluted Earnings Per Share -$0.39 -$0.51 -$407.5K
COMMON SHARES
Basic Shares Outstanding 8.401M shares 8.401M shares 8.259M shares
Diluted Shares Outstanding 8.401M shares 8.401M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.69M $21.68M $36.18M
YoY Change -40.35% -40.07% 256.96%
Cash & Equivalents $12.70M $6.805M $33.22M
Short-Term Investments $6.994M $14.88M $2.961M
Other Short-Term Assets $180.8K $451.7K $742.0K
YoY Change -30.7% -39.12% -63.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.87M $22.15M $36.92M
YoY Change -40.27% -40.0% 203.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.376K $1.698K $150.4K
YoY Change -49.63% -98.87% -90.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $754.7K $754.7K $16.48K
YoY Change 14.52% 4479.66% -99.56%
Total Long-Term Assets $972.0K $992.9K $166.8K
YoY Change 23.56% 495.14% -96.83%
TOTAL ASSETS
Total Short-Term Assets $19.87M $22.15M $36.92M
Total Long-Term Assets $972.0K $992.9K $166.8K
Total Assets $20.84M $23.14M $37.09M
YoY Change -38.8% -37.59% 112.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $747.7K $382.1K $2.835M
YoY Change -69.27% -86.52% 1449.01%
Accrued Expenses $1.355M $1.440M $444.7K
YoY Change 1284.3% 223.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.103M $1.822M $3.680M
YoY Change -41.97% -50.47% -29.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $116.2K $136.7K $50.52K
YoY Change 316.23% 170.53% -94.28%
Total Long-Term Liabilities $116.2K $136.7K $50.52K
YoY Change 316.28% 170.52% -94.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.103M $1.822M $3.680M
Total Long-Term Liabilities $116.2K $136.7K $50.52K
Total Liabilities $2.219M $1.959M $3.730M
YoY Change -39.23% -47.48% -38.71%
SHAREHOLDERS EQUITY
Retained Earnings -$37.50M -$34.20M
YoY Change 63.76%
Common Stock $84.01K $84.01K
YoY Change 1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.63M $21.19M $33.36M
YoY Change
Total Liabilities & Shareholders Equity $20.84M $23.14M $37.09M
YoY Change -38.8% -37.59% 112.77%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.245M -$4.253M -$3.365M
YoY Change -15.39% 26.39% 449.48%
Depreciation, Depletion And Amortization $320.00 $321.00 $530.00
YoY Change -40.74% -39.43% 152.38%
Cash From Operating Activities -$2.107M -$4.962M -$3.118M
YoY Change -33.08% 59.16% 277.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.000M $2.141M -$2.798M
YoY Change -150.6% -176.5%
Cash From Investing Activities $8.000M $2.141M -$2.798M
YoY Change -150.6% -176.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -2.107M -$4.962M -3.118M
Cash From Investing Activities 8.000M $2.141M -2.798M
Cash From Financing Activities
Net Change In Cash 5.893M -$2.822M $0.00
YoY Change -131.09%
FREE CASH FLOW
Cash From Operating Activities -$2.107M -$4.962M -$3.118M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001857044
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 INDP Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss
ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss
usd
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
usd
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
usd
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
usd
CY2022Q1 INDP Cash Received For Interest Earned On Deposits
CashReceivedForInterestEarnedOnDeposits
usd
CY2022Q1 INDP Lease Renewal Option Exercise
LeaseRenewalOptionExercise
usd
CY2022Q1 INDP Reclassification Of Security Deposit
ReclassificationOfSecurityDeposit
usd
CY2022Q4 us-gaap Other Receivables
OtherReceivables
usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40652
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Indaptus Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3158720
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3 Columbus Circle
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2023Q1 dei City Area Code
CityAreaCode
(646)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
427-2727
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.01 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
INDP
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8401047 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805146 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9626800 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
14875693 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16806009 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
470751 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
811433 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
22151590 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27244242 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1698 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2019 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
236506 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
79294 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
754728 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
738251 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
992932 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
819564 usd
CY2023Q1 us-gaap Assets
Assets
23144522 usd
CY2022Q4 us-gaap Assets
Assets
28063806 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1722622 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3352847 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99837 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80494 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1822459 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3433341 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136669 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
136669 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1959128 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3433341 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8401047 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8401047 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8401047 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8401047 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
84011 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
84011 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55170849 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54443705 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34246923 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29993685 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
177457 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
96434 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21185394 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
24630465 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23144522 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28063806 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1879900 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1297098 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2575266 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2104975 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4455166 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3402073 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4455166 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3402073 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
201928 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36919 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4253238 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3365154 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8401047 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8258597 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4253238 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3365154 usd
CY2023Q1 INDP Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss
ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss
-129229 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
210252 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-9221 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4172215 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3374375 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35899580 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
831183 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9221 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3365154 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33356388 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33356388 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
24630465 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
24630465 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
727144 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-129229 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
210252 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4253238 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21185394 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21185394 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4253238 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3365154 usd
CY2023Q1 us-gaap Depreciation
Depreciation
321 usd
CY2022Q1 us-gaap Depreciation
Depreciation
534 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
727144 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
831183 usd
CY2023Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
129229 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
24155 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-324205 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-364708 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1630225 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-925204 usd
CY2023Q1 INDP Increase Decrease In Operating Lease Right Of Use Asset And Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
-1200 usd
CY2022Q1 INDP Increase Decrease In Operating Lease Right Of Use Asset And Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
360 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4962222 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3117728 usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
172555 usd
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
9000000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6859432 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2970681 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2140568 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2798126 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2821654 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5915854 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9626800 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39132165 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6805146 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33216311 usd
CY2023Q1 INDP Cash Received For Interest Earned On Deposits
CashReceivedForInterestEarnedOnDeposits
81023 usd
CY2023Q1 INDP Lease Renewal Option Exercise
LeaseRenewalOptionExercise
236506 usd
CY2023Q1 INDP Reclassification Of Security Deposit
ReclassificationOfSecurityDeposit
16477 usd
CY2023Q1 INDP Supplemental Disclosures Cash Received For Interest Earned On Deposits
SupplementalDisclosuresCashReceivedForInterestEarnedOnDeposits
36123 usd
CY2022Q1 INDP Supplemental Disclosures Cash Received For Interest Earned On Deposits
SupplementalDisclosuresCashReceivedForInterestEarnedOnDeposits
1318 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_808_eus-gaap--NatureOfOperations_zVoXiRFdk3Y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_821_zFJzTn4R1eY4">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”), is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the need for additional capital (or financing) to fund operating losses (see below), competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence on key individuals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to general conditions and macroeconomic factors in the global economy including increasing concerns over banking failures and bailouts and their potential broader effect on the banking sector generally and on the biotechnology industry. Additionally, inflation, rising interest rates, overall economic conditions and uncertainties, and the risk of a severe or prolonged economic downturn could result in a variety of risks, including the Company’s ability to raise additional funding on a timely basis or on acceptable terms and may additionally impact third parties upon which the Company relies to carry out its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going concern and management’s plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred net losses and utilized cash in operations since inception, has an accumulated deficit as of March 31, 2023 of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zjeFdCZ3sF6i" title="Accumulated deficit">34.2</span> million, and expects to incur future additional losses as clinical testing and commercialization of the Company’s product candidates will require significant additional financing. The Company believes it has adequate cash to fund its ongoing activities into the second quarter of 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management plans to raise additional capital through equity and/or debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements. However, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the recent events in the banking sector, ongoing conflict between Russia and Ukraine, and the lingering impact from the COVID-19 pandemic. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve its development and commercialization goals would be adversely affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34200000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_z4Tbq9KqMw56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zHsdl9iBcnta">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the condensed consolidated financial statements; therefore, actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>  </i></span></p>
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
363478 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
610208 usd
CY2023Q1 INDP Prepaid Research And Development
PrepaidResearchAndDevelopment
12689 usd
CY2022Q4 INDP Prepaid Research And Development
PrepaidResearchAndDevelopment
80910 usd
CY2023Q1 us-gaap Other Receivables
OtherReceivables
19062 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
75522 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
120315 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
470751 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
811433 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
382099 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1378316 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
430006 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1216242 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
246295 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
172356 usd
CY2023Q1 INDP Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
472155 usd
CY2022Q4 INDP Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
311036 usd
CY2023Q1 INDP Accrued Board Fees Current
AccruedBoardFeesCurrent
122583 usd
CY2022Q4 INDP Accrued Board Fees Current
AccruedBoardFeesCurrent
116000 usd
CY2023Q1 INDP Delaware Franchise Taxes Payable Current
DelawareFranchiseTaxesPayableCurrent
50000 usd
CY2022Q4 INDP Delaware Franchise Taxes Payable Current
DelawareFranchiseTaxesPayableCurrent
128929 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19484 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29968 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1722622 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3352847 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1672873 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.01
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
255750 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.62
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1928623 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.50
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
791345 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.12
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1928623 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.50
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
59380 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
727144 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
831183 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4200000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2023Q1 INDP Weighted Average Grant Date Fair Value Of Stock Options
WeightedAverageGrantDateFairValueOfStockOptions
1.35
CY2023Q1 us-gaap Share Price
SharePrice
1.62
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.62
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.097 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.035 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1928623 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8401047 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8401047 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8401047 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8401047 shares
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
236506 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
236506 usd
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09 pure
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
74537 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
101705 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
86862 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
263104 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
26598 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
236506 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99837 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136669 usd
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
24356 usd
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
26542 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
24716 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
26182 usd

Files In Submission

Name View Source Status
indp-20230331_def.xml Edgar Link unprocessable
indp-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001493152-23-016268-index-headers.html Edgar Link pending
0001493152-23-016268-index.html Edgar Link pending
0001493152-23-016268.txt Edgar Link pending
0001493152-23-016268-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
indp-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
indp-20230331_lab.xml Edgar Link unprocessable
indp-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending